Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The advent of molecular genetics - fuelled by the progress in DNA sequencing technologies and publication of the landmark Human Genome Project over a decade ago - has had a major impact on our understanding of the architecture of disease, opening up the prospect of personalized medicine based upon knowledge of an individual's genetic variants. Current management of patients with inherited cardiomyopathies is starting to integrate knowledge of an individual's genomic profile together with advancements in cardiovascular imaging. This has enhanced surveillance potential for high-risk individuals and has begun to facilitate diagnosis and, to a lesser extent, appropriate risk stratification and prognostication. This review introduces the reader to the inherited cardiomyopathies (hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy and dilated cardiomyopathy) - representing the first cardiac disorders to be accurately delineated at a molecular genetic level - and provides an insight into their molecular genetic and clinical complexity.

Original publication

DOI

10.1016/j.mpmed.2014.07.004

Type

Journal article

Journal

Medicine (United Kingdom)

Publisher

Elsevier Ltd

Publication Date

01/10/2014

Volume

42

Pages

584 - 590

Keywords

Arrhythmogenic right ventricular dysplasia, cardiomyopathy, dilated cardiomyopathy, genetic, hypertrophic, mutation, sudden cardiac death